+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

Hematopoietic Progenitor Kinase 1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Hematopoietic Progenitor Kinase 1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
From
From
From
From
From
From
Anti-PD-1 / Anti-PD-L1 Refractory Solid Tumors - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-PD-1 / Anti-PD-L1 Refractory Solid Tumors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Bispecific Antibody & Cancer Patent Landscape Analysis - Product Thumbnail Image

Bispecific Antibody & Cancer Patent Landscape Analysis

  • Report
  • January 2025
  • 120 Pages
  • Global
From
From
China Bispecific Antibodies Market and Clinical Pipeline Insight 2028 - Product Thumbnail Image

China Bispecific Antibodies Market and Clinical Pipeline Insight 2028

  • Drug Pipelines
  • August 2023
  • 400 Pages
  • China
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more